Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

12/11 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
18/26/18	SEK 0.4480	+7.31%	37,80,673
17/26/17	SEK 0.4175	-8.74%	51,48,576
16/26/16	SEK 0.4575	-0.33%	17,68,715
15/26/15	SEK 0.4590	-1.18%	29,06,802
14/26/14	SEK 0.4645	-1.28%	24,32,120

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm 09:30:00 18/09/2026 pm IST			5-day change	1st Jan Change
0.4480 ^SEK	+7.31%		-4.78%	-45.96%

11/09	Stockholm stocks ended Friday higher	FW
11/09	Calendar Monday September 14 - Friday September 18	FW

Market Cap	9.08Cr 92.05L 80.26L 75.79L 68.82L 1.29Cr 88Cr 1.29Cr 3.5Cr 45Cr 3.46Cr 3.38Cr 144.49Cr	P/E 2026 *	-1.66x	P/E 2027 *	-1.18x
Enterprise Value	7.48Cr 75.82L 66.12L 62.43L 56.69L 1.06Cr 73Cr 1.07Cr 2.89Cr 37Cr 2.85Cr 2.79Cr 119.02Cr	EV / Sales 2026 *	2.39x	EV / Sales 2027 *	-
Free-Float	46.92%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	ALZ	Delayed
CBOE		Real-time
Deutsche Boerse AG	78D	Delayed
Börse Stuttgart	78D	Delayed
CBOE		Real-time

11/09	Stockholm stocks ended Friday higher	FW
11/09	Calendar Monday September 14 - Friday September 18	FW
11/09	Alzinova: Redeye cuts justified value to SEK 0.90	FW
11/09	Asker plunges on double downgrade, OMXS30 index up 0.3 percent	FW
11/09	Asker plunges on choppy Stockholm market	FW
11/09	Stockholm's stock exchange is expected to open Friday on a mixed note	FW
11/09	Alzinova Resolves On Rights Issue Of SEK 51 Mln	RE
11/09	Alzinova Starts Preparations for Mid-stage Trial of Alzheimer's Disease Vaccine Candidate	MT
11/09	Alzinova AB Initiates Operational Start-Up Of Global Phase 2 Study With ALZ-101	CI
20/08	Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
20/08	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW
20/08	Alzinova reports reduced operating loss	FW
20/08	Calendar Thursday, August 20	FW

Alzinova AB Share Price

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation: Alzinova AB

Chart: Alzinova AB

Latest news: Alzinova AB

Analysts' recommendations: Alzinova AB

Press Releases: Alzinova AB

Quotes and Performance

Price Extremes

Managers and Directors: Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

18/09	Alzinova publishes information memorandum in connection with rights issue of units	AQ
11/09	Alzinova: Phase II study update and SEK51 rights issue	AQ
11/09	Alzinova: ALZ-101 enters Phase II start-up as Alzinova raises capital	AQ
11/09	The Board of Directors of Alzinova resolves on a rights issue of units of approximately SEK 51 million	AQ
11/09	Alzinova initiates operational start-up of global Phase 2 study with ALZ-101	AQ

1 day	+7.31%
1 week	-4.78%
Current month	-44.00%
1 month	-50.22%
3 months	-6.57%
6 months	-26.56%
Current year	-45.96%

1 week	0.4	0.48
1 month	0.4	1.04
Current year	0.38	1.61
1 year	0.38	2.28
3 years	0.38	4.62
5 years	0.38	8.7
10 years	0.38	44.9

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	01/10/2024
Anders Sandberg COO	Chief Operating Officer	54	17/08/2011
Erik Kullgren DFI	Director of Finance/CFO	57	27/03/2024

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	01/09/2015
Anders Waas BRD	Director/Board Member	69	01/01/2018
Carol Routledge BRD	Director/Board Member	-	01/01/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	+7.31%	-4.78%	-61.04%	-85.62%	92.05L
LONZA GROUP AG	+0.11%	+2.71%	+0.33%	+28.59%	4.63TCr
IQVIA HOLDINGS INC.	-1.12%	+1.78%	+40.07%	+27.26%	4.39TCr
REVOLUTION MEDICINES, INC.	-3.04%	-6.29%	+322.27%	+517.36%	4.09TCr
BEONE MEDICINES AG	-0.74%	+1.25%	+2.32%	+67.94%	3.99TCr
CELLTRION, INC.	-0.50%	+0.67%	+11.79%	+40.51%	2.95TCr
MEDPACE HOLDINGS, INC.	-0.46%	+4.22%	+21.99%	+124.21%	1.71TCr
ASCENDIS PHARMA A/S	-0.97%	-10.17%	-	-	1.55TCr
EUROFINS SCIENTIFIC SE	-0.57%	+8.12%	+22.15%	+38.93%	1.52TCr
TEMPUS AI, INC.	-3.14%	+31.91%	-10.60%	-	1.4TCr
Average	-0.16%	+2.91%	+38.81%	+94.90%	2.62TCr
Weighted average by Cap.	-1.02%	+1.87%	+64.69%	+130.22%

	2026 *	2027 *
Net sales	3.14Cr 31.79L 27.72L 26.17L 23.77L 44.53L 31Cr 44.71L 1.21Cr 16Cr 1.19Cr 1.17Cr 50Cr	-
Net income	-44.5L -5L -4L -4L -3L -6L -4.33Cr -6L -17.17L -2.2Cr -16.95L -16.57L -7.08Cr	-7.7Cr -78.07L -68.08L -64.28L -58.37L -1.09Cr -75Cr -1.1Cr -2.97Cr -38Cr -2.93Cr -2.87Cr -122.55Cr
Net Debt	-1.6Cr -16.22L -14.15L -13.36L -12.13L -22.73L -16Cr -22.82L -61.74L -7.91Cr -60.94L -59.59L -25Cr	-1.9Cr -19.26L -16.8L -15.86L -14.4L -26.99L -18Cr -27.1L -73.32L -9.4Cr -72.37L -70.76L -30Cr